CZ299465B6 - Kombinace s obsahem pyridoindolonového derivátu aprotinádorového cinidla - Google Patents

Kombinace s obsahem pyridoindolonového derivátu aprotinádorového cinidla Download PDF

Info

Publication number
CZ299465B6
CZ299465B6 CZ20032910A CZ20032910A CZ299465B6 CZ 299465 B6 CZ299465 B6 CZ 299465B6 CZ 20032910 A CZ20032910 A CZ 20032910A CZ 20032910 A CZ20032910 A CZ 20032910A CZ 299465 B6 CZ299465 B6 CZ 299465B6
Authority
CZ
Czechia
Prior art keywords
methyl
group
hydrogen
formula
ethyl group
Prior art date
Application number
CZ20032910A
Other languages
Czech (cs)
English (en)
Other versions
CZ20032910A3 (en
Inventor
Bourrie@Bernard
Casellas@Pierre
Marie Derocq@Jean
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of CZ20032910A3 publication Critical patent/CZ20032910A3/cs
Publication of CZ299465B6 publication Critical patent/CZ299465B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CZ20032910A 2001-04-27 2002-04-26 Kombinace s obsahem pyridoindolonového derivátu aprotinádorového cinidla CZ299465B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone

Publications (2)

Publication Number Publication Date
CZ20032910A3 CZ20032910A3 (en) 2004-07-14
CZ299465B6 true CZ299465B6 (cs) 2008-08-06

Family

ID=8862882

Family Applications (2)

Application Number Title Priority Date Filing Date
CZ20032910A CZ299465B6 (cs) 2001-04-27 2002-04-26 Kombinace s obsahem pyridoindolonového derivátu aprotinádorového cinidla
CZ20032909A CZ295224B6 (cs) 2001-04-27 2002-04-26 Protinádorová léčiva s obsahem pyridoindolonových derivátů

Family Applications After (1)

Application Number Title Priority Date Filing Date
CZ20032909A CZ295224B6 (cs) 2001-04-27 2002-04-26 Protinádorová léčiva s obsahem pyridoindolonových derivátů

Country Status (33)

Country Link
US (3) US6967203B2 (enExample)
EP (2) EP1385513B1 (enExample)
JP (2) JP2004531538A (enExample)
KR (1) KR100847413B1 (enExample)
CN (2) CN1505511A (enExample)
AR (1) AR034313A1 (enExample)
AT (2) ATE338548T1 (enExample)
BG (2) BG108261A (enExample)
BR (1) BR0209138A (enExample)
CA (2) CA2443012C (enExample)
CY (1) CY1105813T1 (enExample)
CZ (2) CZ299465B6 (enExample)
DE (2) DE60214533T2 (enExample)
DK (2) DK1385513T3 (enExample)
EA (1) EA005930B1 (enExample)
EE (2) EE200300466A (enExample)
ES (2) ES2254683T3 (enExample)
FR (1) FR2823975B1 (enExample)
HU (2) HUP0400745A2 (enExample)
IL (4) IL158312A0 (enExample)
IS (1) IS2441B (enExample)
MX (1) MXPA03009639A (enExample)
NO (2) NO20034785L (enExample)
NZ (1) NZ528671A (enExample)
PL (2) PL366910A1 (enExample)
PT (2) PT1385512E (enExample)
RS (2) RS50791B (enExample)
RU (1) RU2292888C9 (enExample)
SK (2) SK13242003A3 (enExample)
TW (1) TWI252104B (enExample)
UA (1) UA74876C2 (enExample)
WO (2) WO2002087575A1 (enExample)
ZA (1) ZA200307785B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2846329B1 (fr) * 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
FR2765581A1 (fr) * 1997-07-03 1999-01-08 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
EP0581388A1 (en) * 1992-07-30 1994-02-02 Glaxo Group Limited Pyridoindolone Methansulphonate as 5HT and 5HT3 receptor antagonists
ATE386131T1 (de) * 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
FR2765582B1 (fr) 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
JP2002510686A (ja) * 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキルで置換された５，６，７，８−テトラヒドロ−９Ｈ−ピリジノ［２，３−ｂ］インドール及び５，６，７，８−テトラヒドロ−９Ｈピリミジノ［４，５−Ｂ］インドール誘導体：ＣＲＦ１特異的配位子
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
FR2765581A1 (fr) * 1997-07-03 1999-01-08 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
DK1385512T3 (da) 2006-05-22
DE60208365T2 (de) 2006-09-07
EA200301062A1 (ru) 2004-04-29
EE200300466A (et) 2003-12-15
NO20034787D0 (no) 2003-10-24
KR100847413B1 (ko) 2008-07-18
ES2254683T3 (es) 2006-06-16
RS50790B (sr) 2010-08-31
HUP0400745A2 (hu) 2004-08-30
SK13242003A3 (sk) 2004-03-02
IL158266A (en) 2009-09-01
PT1385512E (pt) 2006-05-31
BR0209138A (pt) 2004-06-08
DE60214533D1 (de) 2006-10-19
FR2823975A1 (fr) 2002-10-31
BG108260A (bg) 2004-12-30
US20050272760A1 (en) 2005-12-08
CY1105813T1 (el) 2011-02-02
EP1385512B1 (fr) 2005-12-28
IS2441B (is) 2008-11-15
HUP0400744A2 (hu) 2004-06-28
CZ20032910A3 (en) 2004-07-14
EP1385512A2 (fr) 2004-02-04
FR2823975B1 (fr) 2003-05-30
IL158312A0 (en) 2004-05-12
HK1060066A1 (en) 2004-07-30
ZA200307785B (en) 2004-10-06
CN1505510A (zh) 2004-06-16
UA74876C2 (en) 2006-02-15
RS50791B (sr) 2010-08-31
EP1385513A1 (fr) 2004-02-04
JP2004528343A (ja) 2004-09-16
EA005930B1 (ru) 2005-08-25
WO2002087574A3 (fr) 2003-02-13
ES2271264T3 (es) 2007-04-16
CN1240382C (zh) 2006-02-08
YU83403A (sh) 2006-08-17
US20040122027A1 (en) 2004-06-24
PL366916A1 (en) 2005-02-07
US20040122036A1 (en) 2004-06-24
YU83903A (sh) 2006-08-17
NO20034787L (no) 2003-12-23
NZ528671A (en) 2004-06-25
IL158312A (en) 2009-09-01
CA2443012C (fr) 2009-07-28
PL366910A1 (en) 2005-02-07
MXPA03009639A (es) 2004-06-30
US6967203B2 (en) 2005-11-22
US7160895B2 (en) 2007-01-09
SK13252003A3 (sk) 2004-03-02
DK1385513T3 (da) 2007-01-15
NO20034785L (no) 2003-12-23
RU2292888C9 (ru) 2007-06-20
NO20034785D0 (no) 2003-10-24
WO2002087575A1 (fr) 2002-11-07
EE200300465A (et) 2003-12-15
ATE338548T1 (de) 2006-09-15
BG108261A (bg) 2004-12-30
CN1505511A (zh) 2004-06-16
DE60214533T2 (de) 2007-06-21
CZ20032909A3 (en) 2004-06-16
CA2443012A1 (en) 2002-11-07
HK1059895A1 (en) 2004-07-23
CZ295224B6 (cs) 2005-06-15
US7524857B2 (en) 2009-04-28
ATE314070T1 (de) 2006-01-15
RU2292888C2 (ru) 2007-02-10
RU2003130376A (ru) 2005-04-10
CA2444334A1 (fr) 2002-11-07
PT1385513E (pt) 2007-01-31
EP1385513B1 (fr) 2006-09-06
JP2004531538A (ja) 2004-10-14
KR20040015138A (ko) 2004-02-18
AR034313A1 (es) 2004-02-18
IS6984A (is) 2003-10-09
DE60208365D1 (de) 2006-02-02
IL158266A0 (en) 2004-05-12
TWI252104B (en) 2006-04-01
WO2002087574A2 (fr) 2002-11-07

Similar Documents

Publication Publication Date Title
CA2749843C (en) Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
JP7044375B2 (ja) Ｐｔｐｎ１１の複素環式阻害剤
CA3138197A1 (en) Anti-cancer nuclear hormone receptor-targeting compounds
WO2024193439A1 (zh) Shp2磷酸酶变构抑制剂
CZ299465B6 (cs) Kombinace s obsahem pyridoindolonového derivátu aprotinádorového cinidla
EP4441052B1 (en) Compounds
HK1060066B (en) Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
MXPA06010822A (en) Diphenyl ox-indol-2-on compounds and their use in the treatment of cancer
HK1241722A1 (en) Crystal forms of glutaminase inhibitors
NZ740252B2 (en) Antitumor agent including low-dose irinotecan hydrochloride hydrate

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20100426